Insider Trading Alert - SWI, EMCI And MNTA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 21, 2015, 117 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $233.20 to $1,180,446,250.00.

Highlighted Stocks Traded by Insiders:

SolarWinds (SWI) - FREE Research Report

Hibberd Douglas G, who is EVP, Pres., Bus.Operations at SolarWinds, sold 5,850 shares at $50.00 on May 21, 2015. Following this transaction, the EVP, Pres., Bus.Operations owned 91,646 shares meaning that the stake was reduced by 6% with the 5,850-share transaction.

The shares most recently traded at $48.99, down $1.01, or 2.06% since the insider transaction. Historical insider transactions for SolarWinds go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 15,036
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 15,036
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 48,132

The average volume for SolarWinds has been 510,900 shares per day over the past 30 days. SolarWinds has a market cap of $3.8 billion and is part of the technology sector and computer software & services industry. Shares are down 1.36% year-to-date as of the close of trading on Thursday.

SolarWinds, Inc., together with its subsidiaries, designs, develops, markets, sells, and supports enterprise-class information technology (IT) and infrastructure management software to IT and DevOps professionals in various organizations worldwide. The company has a P/E ratio of 48.2. Currently, there are 6 analysts who rate SolarWinds a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SWI - FREE

TheStreet Quant Ratings rates SolarWinds as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full SolarWinds Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

EMC Insurance Group (EMCI) - FREE Research Report

Reese Mark E, who is Sr. Vice President & CFO at EMC Insurance Group, sold 1,050 shares at $34.70 on May 21, 2015. Following this transaction, the Sr. Vice President & CFO owned 11,955 shares meaning that the stake was reduced by 8.07% with the 1,050-share transaction.

The shares most recently traded at $34.89, up $0.19, or 0.54% since the insider transaction. Historical insider transactions for EMC Insurance Group go as follows:

  • 4-Week # shares sold: 397
  • 12-Week # shares sold: 397
  • 24-Week # shares sold: 1,732

The average volume for EMC Insurance Group has been 12,700 shares per day over the past 30 days. EMC Insurance Group has a market cap of $475.7 million and is part of the financial sector and insurance industry. Shares are down 1.89% year-to-date as of the close of trading on Wednesday.

EMC Insurance Group Inc., an insurance holding company, provides property and casualty insurance, and reinsurance products in the United States. It operates through two segments, Property and Casualty Insurance, and Reinsurance. The stock currently has a dividend yield of 2.89%. The company has a P/E ratio of 11.8. Currently, there are no analysts who rate EMC Insurance Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EMCI - FREE

TheStreet Quant Ratings rates EMC Insurance Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, increase in net income and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full EMC Insurance Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 227 shares at $19.68 on May 21, 2015. Following this transaction, the Senior V.P., Research owned 388,785 shares meaning that the stake was reduced by 0.06% with the 227-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 227 shares at $19.68 on May 21, 2015. Following this transaction, the Svp, Cfo owned 144,048 shares meaning that the stake was reduced by 0.16% with the 227-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 227 shares at $19.68 on May 21, 2015. Following this transaction, the Senior VP, Pharmaceutical Scie owned 110,634 shares meaning that the stake was reduced by 0.2% with the 227-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 227 shares at $19.68 on May 21, 2015. Following this transaction, the SVP & General Counsel owned 117,817 shares meaning that the stake was reduced by 0.19% with the 227-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 360 shares at $19.68 on May 21, 2015. Following this transaction, the Senior VP, Development and Chi owned 105,902 shares meaning that the stake was reduced by 0.34% with the 360-share transaction.

The shares most recently traded at $19.40, down $0.28, or 1.44% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 7,737
  • 12-Week # shares sold: 133,815
  • 24-Week # shares sold: 163,921

The average volume for Momenta Pharmaceuticals has been 1.0 million shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 60.38% year-to-date as of the close of trading on Thursday.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently, there are 4 analysts who rate Momenta Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its unimpressive growth in net income. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec

China Trade Truce, General Electric and Tesla - 5 Things You Must Know

China Trade Truce, General Electric and Tesla - 5 Things You Must Know

GE Shares Gain Amid Reports of $20 Billion Wabtec Deal

GE Shares Gain Amid Reports of $20 Billion Wabtec Deal

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)